Tom J N Hermans1, Elisabeth E Fransen van de Putte1, Simon Horenblas1, Valery Lemmens2, Katja Aben3, Michiel S van der Heijden4, Laurens V Beerepoot5, Rob H Verhoeven6, Bas W G van Rhijn7. 1. Department of Surgical Oncology, Division of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. 2. Department of Research, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands; Department of Public Health, Erasmus University Medical Centre, Rotterdam, The Netherlands. 3. Department of Research, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands; Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands. 4. Department of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. 5. Department of Medical Oncology, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands. 6. Department of Research, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands. 7. Department of Surgical Oncology, Division of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Electronic address: basvanrhijn@hotmail.com.
Abstract
BACKGROUND: In Europe, population-based data concerning perioperative treatment (PT) and radical cystectomy (RC) are lacking. We assessed temporal trends in PT (neoadjuvant chemotherapy [NAC], neoadjuvant radiotherapy [NAR], adjuvant chemotherapy [AC], adjuvant radiotherapy [AR]) and RC in the Netherlands and identified patients' and hospital characteristics associated with PT. METHODS: This nationwide, retrospective, population-based study included cTa/is, T1-4, N0-3, M0-1 bladder cancer patients from the Netherlands Cancer Registry who underwent RC with curative intent between 1995 and 2013. PT-administration over time was compared with chi-square tests. Multivariable logistic regression analyses were performed to identify characteristics associated with PT usage. The sub-groups cT2-4N0M0 and cT2-4, N0 or NX, M0 or MX were separately analysed. RESULTS: In total, 10,338 patients met inclusion criteria. Eighty-six percent did not receive PT, 7.0% received NAC (or induction chemotherapy [IC]), 3.2% NAR, 1.8% AC, and 2.1% AR. NAC usage increased from 0.6% in 1995 to 21% in 2013 (p < 0.001), application of NAR decreased from 15% to 0.4% (p < 0.001). Usage of AC and AR in 2013 was <1.5%. Comparable temporal trends were found in 6032 patients staged cT2-4N0M0. Multivariable logistic regression analysis revealed that younger age, ≥ cT3, ≥ cN1 and treatment in academic/teaching hospitals were associated with NAC or IC (all p < 0.05). CONCLUSIONS: The increase in NAC administration in the Netherlands reflects a slow but steady adoption of evidence-based guidelines over the last two decades. Considerable variability in patients' and hospital characteristics in the likelihood of receiving NAC exists. Conversely, NAR, AR and AC are hardly administered anymore.
BACKGROUND: In Europe, population-based data concerning perioperative treatment (PT) and radical cystectomy (RC) are lacking. We assessed temporal trends in PT (neoadjuvant chemotherapy [NAC], neoadjuvant radiotherapy [NAR], adjuvant chemotherapy [AC], adjuvant radiotherapy [AR]) and RC in the Netherlands and identified patients' and hospital characteristics associated with PT. METHODS: This nationwide, retrospective, population-based study included cTa/is, T1-4, N0-3, M0-1 bladder cancerpatients from the Netherlands Cancer Registry who underwent RC with curative intent between 1995 and 2013. PT-administration over time was compared with chi-square tests. Multivariable logistic regression analyses were performed to identify characteristics associated with PT usage. The sub-groups cT2-4N0M0 and cT2-4, N0 or NX, M0 or MX were separately analysed. RESULTS: In total, 10,338 patients met inclusion criteria. Eighty-six percent did not receive PT, 7.0% received NAC (or induction chemotherapy [IC]), 3.2% NAR, 1.8% AC, and 2.1% AR. NAC usage increased from 0.6% in 1995 to 21% in 2013 (p < 0.001), application of NAR decreased from 15% to 0.4% (p < 0.001). Usage of AC and AR in 2013 was <1.5%. Comparable temporal trends were found in 6032 patients staged cT2-4N0M0. Multivariable logistic regression analysis revealed that younger age, ≥ cT3, ≥ cN1 and treatment in academic/teaching hospitals were associated with NAC or IC (all p < 0.05). CONCLUSIONS: The increase in NAC administration in the Netherlands reflects a slow but steady adoption of evidence-based guidelines over the last two decades. Considerable variability in patients' and hospital characteristics in the likelihood of receiving NAC exists. Conversely, NAR, AR and AC are hardly administered anymore.
Authors: Mathilde B H Thomsen; Iver Nordentoft; Philippe Lamy; Søren Høyer; Søren Vang; Jakob Hedegaard; Michael Borre; Jørgen B Jensen; Torben F Ørntoft; Lars Dyrskjøt Journal: Mol Oncol Date: 2016-08-17 Impact factor: 6.603
Authors: Ronald Kool; Ivan Yanev; Tarek Hijal; Marie Vanhuyse; Fabio L Cury; Luis Souhami; Wassim Kassouf; Alice Dragomir Journal: Can Urol Assoc J Date: 2022-06 Impact factor: 2.052
Authors: Melanie Walker; R Christopher Doiron; Simon D French; Deb Feldman-Stewart; D Robert Siemens; William J Mackillop; Christopher M Booth Journal: Can Urol Assoc J Date: 2017-12-22 Impact factor: 1.862
Authors: Juan J Andino; Michael Sessine; Udit Singhal; Zachery R Reichert; Daniel Wray; Christine Shafer; Marissa Moore; Alon Z Weizer; Samuel D Kaffenberger; Lindsey A Herrel; Todd M Morgan; Khaled Z Hafez; Jeffrey S Montgomery Journal: Urol Pract Date: 2020-10-14
Authors: Alexander Tamalunas; Gerald B Schulz; Severin Rodler; Maria Apfelbeck; Christian G Stief; Jozefina Casuscelli Journal: Urologe A Date: 2021-02 Impact factor: 0.639
Authors: Melanie Walker; R Christopher Doiron; Simon D French; Kelly Brennan; Deb Feldman-Stewart; D Robert Siemens; William J Mackillop; Christopher M Booth Journal: Bladder Cancer Date: 2018-01-20